{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026988","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.226668+00:00","generated_at":"2026-06-12T08:07:56.184677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Avalo Q2 2023: AVTX-002 misses Phase 2 asthma endpoint; cash $6.3M, debt forbearance","bullets":["AVTX-002 did not meet primary endpoint (asthma-related events) in Phase 2 PEAK non-eosinophilic asthma trial.","Net loss of $8.2M for Q2 2023; product revenue of $643K.","Cash $6.3M at June 30, 2023, down from $13.2M at Dec 31, 2022; $6M loan prepaid in June.","Forbearance agreement with lenders until Aug 15, 2023 due to material adverse change event of default.","Exploring sale or out-licensing of assets; non-binding LOI for AVTX-801/802/803."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026988","json":"https://secwatch.observer/filing/0001628280-23-026988.json","markdown":"https://secwatch.observer/filing/0001628280-23-026988.md","text":"https://secwatch.observer/filing/0001628280-23-026988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/0001628280-23-026988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/avtx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:07:56.184677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb6d86bde2a1654fe3fba094d0a1baec183c37c9","claim":"Avalo Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/0001628280-23-026988-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}